TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD
TEVA Latest News, Press Relases and Analysis
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ...
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET
Mentions: SNY
Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?
AMSTERDAM, 21 févr. 2025 (GLOBE NEWSWIRE) -- Une nouvelle étude de Teva Pharmaceuticals Europe révèle que 46 % des médicaments génériques figurant...
Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern
AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der...
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Mentions: AXSM
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab)...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Mentions: ALVO
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.
Mentions: AVGO
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Mentions: ALVO
Teva Pharmaceutical Posts Lower Revenue. Stock Slips.
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.
MarketBeat Week in Review – 02/03 - 02/07
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6 billion in revenues,...
